Overview


According to FutureWise analysis the market for otic drugs is expected to reach US$ 2.75 billion by 2031 at a CAGR of 6.6%.

Otic is a term referring to the ear. Otic ganglion, nerve cells in the ear, Otic polyp, benign growth in middle ear, Otic capsule, another name for bony labyrinth, Otic drops, another name for ear drops, otic notch, a notch in some species of skulls, otic pit, developmental stage of ear, Otic placode, developmental stage of ear, Otic vesicle, developmental stage of ear. Medications used to treat ear infections are called otic medicines. An upper respiratory tract infection causes otitis media, an inflammation of the middle ear that affects the eustachian tube. There is a tube connecting the middle ear to the throat and the ear called the eustachian tube. During this condition, the middle ear fluid does not drain properly, which results in a build-up of fluid behind the eardrum. An infection develops in the ear when the fluid in the ear does not drain, resulting in acute otitis media. Globally, the OTC Topical Drugs Market is driven by skin diseases and musculoskeletal pain.

Global OTC topical drugs market growth is also expected to be driven by increasing health expenditures, a growing population, an aging population, and an increase in disposable income in several developing countries. Several pharmaceutical companies are focused on introducing and receiving medical approval for famous prescription topical drugs under the OTC category with the same dosage form, population, and route of administration. A company's prescription portfolio is reduced through the use of this strategy, and new products are brought to the OTC category, while mature prescription drugs are kept on the market for a longer period of time. Over the past year, otic drop prices have been volatile, with overall price increases exceeding inflation. There is no transparency in drug pricing, making it difficult for prescribers and patients to make cost-conscious choices. You have been prescribed this medication because your doctor deemed the benefit to you greater than the risk of side effects. The side effects of this medication are generally not serious for most people who use it.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Otic Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Otic Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Pediapharm Novus Therapeutics Inc
  • Eli Lilly and Company
  • F.Hoffmann La Roche Ltd
  • Abbott
  • Mylan N.V.
  • Alcon
  • GlaxoSmithKline Plc
  • Zydus Pharmaceuticals
  • Bayer AG
  • Amneal Pharmaceuticals
  • Novartis AG
  • Merz Pharma
  • Sanofi
  • Sound Pharmaceuticals
  • Bristol-Myers Squibb Company
  • Intas Pharmaceuticals Ltd
  • Otonomy Inc
  • Torrent Pharmaceuticals Ltd

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • Acute Otitis Media
  • Otitis Media with Effusion
  • Chronic Otitis Media with Effusion

By Route of Administration

  • Oral
  • Topical
  • Injectable
  • Others

By Distribution Channel

  • Hospitals pharmacies
  • Drug Stores
  • Retail Stores
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Otic Drugs Market By Type, By Route of Administration, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Otic Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Otic Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Otic Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Otic Drugs Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Acute Otitis Media
        2. Otitis Media with Effusion
        3. Chronic Otitis Media with Effusion

  • 8.   Otic Drugs Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Topical
        3. Injectable
        4. Others

  • 9.   Otic Drugs Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals pharmacies
        2. Drug Stores
        3. Retail Stores
        4. Others

  • 10.   North America Otic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Otic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Otic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Otic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Pediapharm Novus Therapeutics Inc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Eli Lilly and Company
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. F.Hoffmann La Roche Ltd
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Abbott
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Mylan N.V.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Alcon
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. GlaxoSmithKline Plc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Zydus Pharmaceuticals
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Bayer AG
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Amneal Pharmaceuticals
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
         11. Novartis AG
          11.1. Company Overview
          11.2. Product Portfolio
          11.3. SWOT Analysis
          11.4. Financial Overview
          11.5. Strategic Overview
         12. Merz Pharma
          12.1. Company Overview
          12.2. Product Portfolio
          12.3. SWOT Analysis
          12.4. Financial Overview
          12.5. Strategic Overview
         13. Sanofi
          13.1. Company Overview
          13.2. Product Portfolio
          13.3. SWOT Analysis
          13.4. Financial Overview
          13.5. Strategic Overview
         14. Sound Pharmaceuticals
          14.1. Company Overview
          14.2. Product Portfolio
          14.3. SWOT Analysis
          14.4. Financial Overview
          14.5. Strategic Overview
         15. Bristol-Myers Squibb Company
          15.1. Company Overview
          15.2. Product Portfolio
          15.3. SWOT Analysis
          15.4. Financial Overview
          15.5. Strategic Overview
        16. Intas Pharmaceuticals Ltd
          16.1. Company Overview
          16.2. Product Portfolio
          16.3. SWOT Analysis
          16.4. Financial Overview
          16.5. Strategic Overview
         17. Otonomy Inc
          17.1. Company Overview
          17.2. Product Portfolio
          17.3. SWOT Analysis
          17.4. Financial Overview
          17.5. Strategic Overview
         18. Torrent Pharmaceuticals Ltd
          18.1. Company Overview
          18.2. Product Portfolio
          18.3. SWOT Analysis
          18.4. Financial Overview
          18.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients